SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Reset Therapeutics, Inc., announced today a collaboration with an affiliate of Alkermes plc for the discovery, development and commercialization of novel orexin receptor modulators from Reset’s drug discovery platform. The orexin system is a key modulator of wakefulness, appetite and mood, and its dysregulation is associated with central nervous system (CNS) disorders such as narcolepsy and depression. “Alkermes is an ideal partner with whom to adva
![]()
↧